Argenica Therapeutics Limited is a biotechnology company focused on developing neuroprotective therapeutics, primarily targeting conditions that result in acute brain injury. Its lead candidate, ARG-007, is a proprietary, arginine-rich peptide designed to reduce brain tissue death and improve patient outcomes following stroke and other neurological trauma, such as traumatic brain injury and hypoxic ischemic encephalopathy. This investigational drug has shown promising results in preclinical studies and completed a Phase 1 clinical trial, establishing its safety and tolerability; it is now undergoing Phase 2 trials in acute ischaemic stroke patients across Australia. Argenica Therapeutics collaborates with renowned academic partners, including the University of Western Australia and the Perron Institute, to expedite research and development. The company serves a critical role in the healthcare sector by addressing a significant unmet need for early intervention therapeutics that protect neural tissue until specialized medical care can be provided. Founded in 2019 and based in Nedlands, Western Australia, Argenica aims to deliver innovative solutions that could fundamentally reshape management and prognosis of neurovascular emergencies.